Evidence map›Paper›PMID 28981484›Full record

ArticleMMWR. Morbidity and mortality weekly report2017

Human Adenovirus Surveillance - United States, 2003-2016.

Alison M Binder, Holly M Biggs, Amber K Haynes, Christina Chommanard, Xiaoyan Lu, Dean D Erdman, John T Watson, Susan I Gerber

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in MMWR. Morbidity and mortality weekly report, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 80 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
80citing papers in PubMed, 5 pooled it
9.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

80 citing papers in PubMed, 5 syntheses or guidelines pooled it, 133 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Guideline
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

20 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Alison M BinderDivision of Viral Diseases, National Center for Immunization and Respiratory Disease, CDC.
Holly M BiggsDivision of Viral Diseases, National Center for Immunization and Respiratory Disease, CDC.
Amber K HaynesDivision of Viral Diseases, National Center for Immunization and Respiratory Disease, CDC.
Christina ChommanardDivision of Viral Diseases, National Center for Immunization and Respiratory Disease, CDC.
Xiaoyan LuDivision of Viral Diseases, National Center for Immunization and Respiratory Disease, CDC.
Dean D ErdmanDivision of Viral Diseases, National Center for Immunization and Respiratory Disease, CDC.
John T WatsonDivision of Viral Diseases, National Center for Immunization and Respiratory Disease, CDC.
Susan I GerberDivision of Viral Diseases, National Center for Immunization and Respiratory Disease, CDC.
National Center for Immunization and Respiratory Diseases · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human adenoviruses (HAdVs) are nonenveloped, double-stranded DNA viruses in the family Adenoviridae; seven species (A-G) and >60 genotypes are known to cause human infection (1). Clinical manifestations associated with HAdV infection include fever, acute respiratory illness, gastroenteritis, and conjunctivitis. HAdV infection can be severe, particularly among immunocompromised patients, and can cause respiratory failure, disseminated infection, hemorrhagic cystitis, neurologic disease, and death (1,2). Illness tends to occur sporadically and without demonstrated seasonality. Outbreaks of HAdV have been reported globally in communities (3), and in closed or crowded settings, including dormitories, health care settings, and among military recruits, for whom a vaccine against HAdV type 4 (HAdV-4) and HAdV type 7 (HAdV-7) has been developed (4,5). CDC summarized HAdV detections voluntarily reported through the National Adenovirus Type Reporting System (NATRS) after initiation of surveillance in 2014 to describe trends in reported HAdVs circulating in the United States. Reporting laboratories were also encouraged to report available results for specimens collected before surveillance began. Overall, the number of reporting laboratories and HAdV type identifications reported to NATRS has increased substantially from the start of official reporting in 2014 through 2016; this report describes specimens collected during 2003-2016. The most commonly reported HAdV types were HAdV type 3 (HAdV-3) and HAdV type 2 (HAdV-2), although HAdV types reported fluctuated considerably from year to year. In the United States, information on recently circulating HAdV types is needed to inform diagnostic and surveillance activities by clinicians and public health practitioners. Routine reporting to NATRS by all U.S. laboratories with the capacity to type HAdVs could help strengthen this surveillance system.

Indexed as

Population SurveillanceAdenoviruses, HumanAdenovirus Infections, HumanHumansUnited States

Identifiers

PMID28981484
PMCPMC5720882
OpenAlexW2761517526

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.